Home > Pulmonology > Trial confirms benefit of SLIT for dust mite allergy

Trial confirms benefit of SLIT for dust mite allergy


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Journal of Allergy and Clinical Immunology
Reuters Health - 16/09/2020 - A sublingual tablet containing house dust mite (HDM) extract is effective for reducing allergic rhinitis symptoms (AR), a new phase-3 trial shows. Over 12 months of treatment, patients randomized to the 300 index of reactivity (IR) sublingual immunotherapy (SLIT) tablet, developed by Stallergenes Greer (Antony, France), also used significantly less medication for their symptoms and had a better quality of life. However, there were more serious adverse events in the active-treatment group. HDM allergens are nearly impossible for allergic individuals to avoid, and only symptomatic treatments for AR are available, Dr. Pascal Demoly of Hopital Arnaud de Villeneuve in Montpellier, France, and colleagues note in the Journal of Allergy and Clinical Immunology. Trials of the 300 IR tablet, containing Dermatophagoides pteronyssinus and D. farinae extract in a total allergenic activity ratio of 1:1, have been conducted in Europe, Canada an...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on